Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2017.429 | Can Positive Psychological Intervention (PPI) improve psychological well-being among Chinese University students? A randomized control trial of Best Possible Self (BPS) Intervention |
Dr. MO Phoenix Kit Han 巫潔嫻 |
| 2017.062 | Positive Psychology Intervention in improving emotion regulation and risky sexual behaviors among men who have sex with men - a randomized controlled trial |
Prof. MO Phoenix Kit Han 巫潔嫻 |
| 2014.348 | Positive psychology intervention for parents of children with Attention Deficit Hyperactivity Disorder (ADHD): Randomized controlled trial | Research Assistant Professor Mo Phoenix Kit Han |
| 2016.720 | A cluster randomized controlled trial to test the efficacy of a theory-based and setting-based intervention in promoting strength training among older adults in Hong Kong |
Ms. MO Phoenix Kit Han 巫潔嫻 |
| 2014.347 | A randomised controlled trial evaluating efficacy of a psychological intervention based on Commonsense Model in improving mental health and self-care among Type-2 Diabetes Mellitus patients | Prof. MO Phoenix Kit Han |
| 2026.248 | Peer-led Motivational Interviewing and Implementation Intentions Intervention for Men Who Have Sex with Men in Hong Kong: A Randomized Controlled Trial to Promote Condom Use | Prof. Mo Phoenix Kit Han |
| 2014.274 | The efficacy of using online narratives in changing HIV risk perceptions and behaviours among men who have sex with men in Hong Kong | Prof. MO Phoenix Kit Han |
| 2013.043 | Effectiveness of an Integrated Social Skills Training (ISST) with Social Cognition Component for people with Schizophrenia: A Clinical Control Trial | Ms Mo Sung Yu, Chloe |
| 2025.510 | Accuracy of magnetic resonance imaging in diagnosing leptomeningeal metastasis from lung carcinoma – a 10-year retrospective analysis in a tertiary referral hospital |
Dr. MO Tsun Ming 毛浚銘 |
| 2016.355 | Burnout among physician engaged in palliative care in Hong Kong public hospitals -- BUPPALHO study | Dr. MOK Alice Ka Wai |
| 2017.612 | A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s Disease (AD) |
Prof. MOK Chung Tong 莫仲棠 |
| 2007.502 | Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release to 10 mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer | Professor Mok Chung Tong Vincent |
| 2014.221 | Pilot study on Microelectronic Neural Bridge in improving rehabilitation outcome for stroke patients with upper limb paresis | Professor MOK chung tong Vincent |
| 2007.454 | Occupational and Parkinson's Disease in Hong Kong - A Case-Control Study | Prof. MOK Chung Tong, Vincent |
| 2008.319 | Effect of LY450139, A | Dr MOK Chung Tong, Vincent |
| 2020.394 | Corneal Nerve Changes in Herpes Zoster Ophthalmicus |
Dr. MOK Eugenie 莫曉瑜 |
| 2024.700 | Comparing efficacy of oral azithromycin versus topical azithromycin in the treatment of meibomian gland dysfunction using in vivo confocal microscopy | Dr. MOK Eugenie |
| 2026.491 | Corneal Nerve Changes 5-years after Herpes Zoster Ophthalmicus | Dr. Mok Eugenie |
| 2026.084 | Role of radiation therapy in oligometastatic / oligoprogressive breast cancer | Dr. MOK Florence Siu Ting |
| 2014.477 | Phase II Trial of Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR) | Dr. MOK Florence Siu Ting |
| 2020.472 | Retrospective Cohort Study of Lung Cancer in Hong Kong |
Dr. MOK Florence Siu Ting 唐美思 |
| 2020.099 | Hong Kong Real-World Data Analytics and Genomic-Guided Therapy Research Project | Dr. MOK Florence Siu Ting |
| 2020.463 | Outcomes and hearing loss after definitive Intensity Modulated Radiotherapy (IMRT) in Nasopharyngeal carcinoma: Dose effect and toxicity relationship |
Dr. MOK Florence Siu Ting 莫小婷 |
| 2011.232 | Sleep Disturbance in Chinese Palliative Care Patients and Its Impact on Quality of Life | Dr Mok Ka Wai Alice |
| 2017.028 | Relationship between knee kinematics and functional performance during an isometric single-leg squat |
Dr. MOK Kam Ming 莫鑑明 |
| 2013.645 | Clinical siginificance and functional effects of NCOA2 in colorectal cancer | Dr Mok Myth Tsz Shun |
| 2010.083 | High Performance Multi-pinhole SPECT for Clinical and Preclinical Molecular Imaging | Dr Mok Seng Peng, Greta |
| 2013.448 | Streamlining workflow by using water instead of iodinated oral contrast for CT Abdomen & Pelvis | Ms. MOK Serena Sum Yee |
| 2011.573 | A retrospective review on the use of erythropoiesis-stimulating agents in peritoneal dialysis patients in an acute hospital in Hong Kong | Ms. MOK Shirley Siu Man |
| 2022.334 | HERTHENA–Lung02: A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy |
Prof. MOK Shu Kam 莫樹錦教授 |
| 2012.225 | A Randomized, Phase III, Multicenter, Double Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MetMAb in Combination With Tarceva (Erlotinib) in Patients with Met Diagnostic-Positive Non-Small Cell Lung Cancer (NSCLC) who have Received Standard Chemotherapy for Advanced or Metastatic Disease | Prof. Mok Shu-Kam |
| 2020.341 | To determine the clinical effect of Local ablative radiotherapy such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS) on various metastatic cancers | Dr. MOK Siu Ting |
| 2016.229 | Stereotactic Radiosurgery (SRS)/ Radiotherapy (SRT) for Brain Metastases: A Review of Outcomes and Prognostic Scores Evaluation |
Dr Mok SIU TING 莫小婷 |
| 2026.290 | Cardiac Substructure Dose and Cardiac Events in Lung SBRT: A Multi-Center Retrospective Analysis (HKSBRTSG Research Project) | Dr. Mok Siu Ting |
| 2005.209 | The Health-Related Quality of Life of Chronic Hepatits B Carriers in Hong Kong | MOK Suet Yuk |
| 2010.228 | Mapping of activating and resistant EGFR mutations in pulmonary adenocarcinoma | Professor Mok Tony |
| 2013.021 | A Survey of the Current Status of EGFR Mutation Testing in Asia | Prof. Mok Tony |
| 2018.434 | An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bintrafusp alfa) versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer |
Prof. MOK Tony 莫樹錦教授 |
| 2018.394 | The Circulating Cell-free Genome Atlas in Asia (CCGAsia) Study |
Prof. MOK Tony 莫樹錦教授 |
| 2020.025 | A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations |
Prof. MOK Tony 莫樹錦教授 |
| 2009.248 | A randomized phase II study comparing acupuncture to acupuncture with moxibustion on reduction of chemotherapy-induced neutropenia | Prof. Mok Tony |
| 2011.602 | A Phase III Randomised, Double blind, Placebo controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of continuing IRESSATM 250 mg in addition to Chemotherapy versus Chemotherapy alone in Patients who have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and have progressed on First Line IRESSATM. IMPRESS- (IRESSATM Mutation Positive Multicentre Treatment Beyond ProgRESsion Study) | Prof. MOK Tony |
| 2009.010 | A Phase II Study to Evaluate the Effectiveness of Acupuncture in Treating Chemotherapy Induced Peripheral Neuropathy (CIPN) | Prof. Mok Tony |
| 2008.583 | A randomised, placebo-controlled, double-blind phase III study of intercalated Tarceva_ (erlotinib) or placebo with gemcitabine/platinum as first-line treatment in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) | Prof. MOK Tony |
| 2008.056 | Phase IIb/III Randomized, Double-Blind Trial of BIBW 2992 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Non-Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib | Professor Mok Tony |
| 2014.257 | A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Patients with Locally Advanced/Metastatic Non Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours are Epidermal Growth Factor Receptor Mutation and T790M Mutation Positive (AURA2) | Prof. MOK Tony |
| 2011.396 | A Randomized Double Blind Phase 3 Efficacy And Safety Study Of PF-00299804 Versus Erlotinib For The Treatment Of Advanced Non-Small Cell Lung Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy | Prof. MOK Tony |
| 2009.392 | LUX-Lung 3; A randomised, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation | Prof. MOK Tony |
| 2009.595 | A Phase 1B/2 Study of SCH 900105 in Combination with Gefitinib in Asian Subjects with Non-Small Cell Lung Cancer | Prof. Mok Tony |
| 2009.331 | Clinical Application of Epidermal Growth Factor Receptor (EGFR) Mutation as Predictive Biomarker for EGFR Tyrosine Kinase Inhibitor (TKI) in Never/Light-Smoker with Adenocarcinoma of Lung | Prof. MOK Tony |
Page 183 of 288.